BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905-2912. [PMID: 17763428 DOI: 10.1002/art.22809] [Cited by in Crossref: 392] [Cited by in F6Publishing: 323] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 2012;14:343-8. [PMID: 22562431 DOI: 10.1007/s11926-012-0260-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
2 Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med. 2013;126:730.e9-730.e17. [PMID: 23885678 DOI: 10.1016/j.amjmed.2013.02.016] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
3 Ljung L, Askling J, Rantapää-Dahlqvist S, Jacobsson L; ARTIS Study Group. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014;16:R127. [PMID: 24941916 DOI: 10.1186/ar4584] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
4 Szekanecz Z, Szántó S, Szabó Z, Váncsa A, Szamosi S, Bodnár N, Szücs G. Biologics - beyond the joints. Autoimmun Rev 2010;9:820-4. [PMID: 20667515 DOI: 10.1016/j.autrev.2010.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
5 Kramer HR, Giles JT. Cardiovascular disease risk in rheumatoid arthritis: Progress, debate, and opportunity. Arthritis Care Res 2011;63:484-99. [DOI: 10.1002/acr.20386] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
6 Tsai WC, Ou TT, Yen JH, Wu CC, Tung YC. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One 2015;10:e0126347. [PMID: 25970845 DOI: 10.1371/journal.pone.0126347] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
7 Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY, Gottlieb AB. Psoriasis. Nat Rev Dis Primers 2016;2:16082. [PMID: 27883001 DOI: 10.1038/nrdp.2016.82] [Cited by in Crossref: 238] [Cited by in F6Publishing: 194] [Article Influence: 47.6] [Reference Citation Analysis]
8 Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards CJ. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518-531. [PMID: 21071477 DOI: 10.1093/rheumatology/keq316] [Cited by in Crossref: 147] [Cited by in F6Publishing: 123] [Article Influence: 13.4] [Reference Citation Analysis]
9 Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatologic Therapy 2010;23:137-43. [DOI: 10.1111/j.1529-8019.2010.01307.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
10 Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. Arthritis Care Res 2019;71:1004-18. [DOI: 10.1002/acr.23737] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
11 Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis. Expert Opinion on Therapeutic Targets 2008;12:1085-96. [DOI: 10.1517/14728222.12.9.1085] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
12 Laws PM, Young HS. Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol 2010;3:25-37. [PMID: 21437057 DOI: 10.2147/ccid.s6497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Ward MM. Interpreting studies of cardiovascular mortality in rheumatoid arthritis: The importance of timing. Arthritis Rheum 2008;59:1687-9. [DOI: 10.1002/art.24170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
14 Palmer D, El Miedany Y. From guidelines to clinical practice: cardiovascular risk management in inflammatory arthritis patients. Br J Community Nurs 2013;18:424-8. [PMID: 24005485 DOI: 10.12968/bjcn.2013.18.9.424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Rodríguez-Carrio J, Alperi-López M, López P, Alonso-Castro S, Ballina-García FJ, Suárez A. Red cell distribution width is associated with cardiovascular risk and disease parameters in rheumatoid arthritis.Rheumatology (Oxford). 2015;54:641-646. [PMID: 25239880 DOI: 10.1093/rheumatology/keu345] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
16 Macmullan PA, Madigan AM, Paul N, Peace AJ, Alagha A, Nolan KB, Mccarthy GM, Kenny D. Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol 2016;35:447-55. [DOI: 10.1007/s10067-014-2769-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
17 Peluso R, Caso F, Tasso M, Ambrosino P, Dario Di Minno MN, Lupoli R, Criscuolo L, Caso P, Ursini F, Puente AD, Scarpa R, Costa On Behalf Of CaRRDs Study Group L. Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients. Rev Recent Clin Trials 2018;13:199-209. [PMID: 29542417 DOI: 10.2174/1574887113666180314105511] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
18 Sen D, González-Mayda M, Brasington RD. Cardiovascular disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2014;40:27-49. [PMID: 24268008 DOI: 10.1016/j.rdc.2013.10.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
19 Ajeganova S, Svensson B, Hafström I; BARFOT Study Group. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open 2014;4:e004259. [PMID: 24710131 DOI: 10.1136/bmjopen-2013-004259] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
20 Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology (Oxford) 2013;52:204-9. [PMID: 23065359 DOI: 10.1093/rheumatology/kes272] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
21 Martínez-Hervás S, González-Navarro H. Anti-inflammatory Therapies for Cardiovascular Disease: Signaling Pathways and Mechanisms. Rev Esp Cardiol (Engl Ed) 2019;72:767-73. [PMID: 31155366 DOI: 10.1016/j.rec.2019.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Rodríguez Lozano C. Seguridad de las terapias biológicas: nuevos datos de BIOBADASER. Reumatología Clínica 2011;6:1-6. [DOI: 10.1016/j.reuma.2010.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Boehncke W, Boehncke S. Managing Comorbidities in Psoriasis. Actas Dermo-Sifiliográficas 2009;100:22-7. [DOI: 10.1016/s0001-7310(09)73374-5] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
24 Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 2011;8:13-21. [PMID: 22083220 DOI: 10.1038/nrrheum.2011.168] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
25 Rutherford A, Nikiphorou E, Galloway J. Rheumatoid Arthritis. In: El Miedany Y, editor. Comorbidity in Rheumatic Diseases. Cham: Springer International Publishing; 2017. pp. 53-79. [DOI: 10.1007/978-3-319-59963-2_3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Szekanecz Z, Kerekes G, Shoenfeld Y. Anti-Inflammatory Therapeutic Approaches. In: Wick G, Grundtman C, editors. Inflammation and Atherosclerosis. Vienna: Springer; 2012. pp. 513-28. [DOI: 10.1007/978-3-7091-0338-8_26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, Safford MM, Kent ST, Osterman MT, Lewis JD, Saag K, Singh JA, Curtis JR. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1813-8. [PMID: 26792814 DOI: 10.1136/annrheumdis-2015-207870] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 11.4] [Reference Citation Analysis]
28 Fragoulis GE, Soulaidopoulos S, Sfikakis PP, Dimitroulas T, D Kitas G. Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction. J Inflamm Res 2021;14:1915-31. [PMID: 34017189 DOI: 10.2147/JIR.S282691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008;159 Suppl 2:2-9. [PMID: 18700909 DOI: 10.1111/j.1365-2133.2008.08779.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
30 Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010;62:755-763. [PMID: 20535785 DOI: 10.1002/acr.20129] [Cited by in Crossref: 129] [Cited by in F6Publishing: 92] [Article Influence: 11.7] [Reference Citation Analysis]
31 Castañeda S, Martín-martínez MA, González-juanatey C, Llorca J, García-yébenes MJ, Pérez-vicente S, Sánchez-costa JT, Díaz-gonzalez F, González-gay MA. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. Seminars in Arthritis and Rheumatism 2015;44:618-26. [DOI: 10.1016/j.semarthrit.2014.12.002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
32 An J, Alemao E, Reynolds K, Kawabata H, Solomon DH, Liao KP, Niu F, Cheetham TC. Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis. J Rheumatol 2016;43:1989-96. [PMID: 27585690 DOI: 10.3899/jrheum.160110] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
33 Akiyama M, Mawatari T, Nakashima Y, Miyahara H, Yamada H, Okazaki K, Fukushi J, Kondo M, Kishimoto J, Hashimura C, Iwamoto Y. Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment. Clin Rheumatol 2015;34:1867-75. [DOI: 10.1007/s10067-015-3049-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
34 Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2010;62:3145-3153. [PMID: 20662063 DOI: 10.1002/art.27660] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
35 Stylianides A, Jones MN, Stewart RM, Murphy CC, Goodson NJ, Kaye SB. Rheumatoid Arthritis–Associated Corneal Ulceration: Mortality and Graft Survival. Ophthalmology 2013;120:682-6. [DOI: 10.1016/j.ophtha.2012.09.050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
36 Gisondi P, Farina S, Giordano MV, Girolomoni G. Usefulness of the Framingham Risk Score in Patients With Chronic Psoriasis. The American Journal of Cardiology 2010;106:1754-7. [DOI: 10.1016/j.amjcard.2010.08.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
37 Fairweather D, Petri MA, Coronado MJ, Cooper LT. Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. Expert Rev Clin Immunol 2012;8:269-84. [PMID: 22390491 DOI: 10.1586/eci.12.10] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
38 Bili A, Tang X, Pranesh S, Bozaite R, Morris SJ, Antohe JL, Kirchner HL, Wasko MCM. Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis: CVD Risk and TNFα in RA. Arthritis Care & Research 2014;66:355-63. [DOI: 10.1002/acr.22166] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
39 Mitchell NE, Harrison N, Junga Z, Singla M. Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24:2322-2326. [PMID: 29788235 DOI: 10.1093/ibd/izy157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
40 Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford). 2012;51 Suppl 6:vi37-vi43. [PMID: 23221586 DOI: 10.1093/rheumatology/kes283] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 9.0] [Reference Citation Analysis]
41 Levesque A, Lachaine J, Bissonnette R. Risk of Myocardial Infarction in Canadian Patients with Psoriasis: A Retrospective Cohort Study. J Cutan Med Surg 2013;17:398-403. [DOI: 10.2310/7750.2013.13052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
42 Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis. 2013;227:216-221. [PMID: 23332774 DOI: 10.1016/j.atherosclerosis.2012.12.029] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 9.6] [Reference Citation Analysis]
43 Sun Z, Hesler BD, Makarova N, Dalton JE, Doan M, Moraska A, De Oliveira G, Turan A. The Association Between Rheumatoid Arthritis and Adverse Postoperative Outcomes: A Retrospective Analysis. Anesthesia & Analgesia 2016;122:1887-93. [DOI: 10.1213/ane.0000000000001066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
44 Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Kynaston-Pearson FJ. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2014;:CD007649. [PMID: 25231904 DOI: 10.1002/14651858.CD007649.pub3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
45 Giollo A, Bissell LA, Buch MH. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. Expert Opin Drug Saf 2018;17:697-708. [PMID: 29871535 DOI: 10.1080/14740338.2018.1483331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
46 Tam L, Shang Q, Li EK, Wang S, Li R, Lee K, Leung Y, Ying K, Yim C, Kun EW, Leung M, Li M, Li TK, Zhu TY, Chui RK, Tseung L, Yu S, Kuan W, Yu C. Infliximab is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis — A Randomized Trial. J Rheumatol 2012;39:2267-75. [DOI: 10.3899/jrheum.120541] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
47 Zha AM, Di Napoli M, Behrouz R. Prevention of Stroke in Rheumatoid Arthritis. Curr Neurol Neurosci Rep 2015;15:77. [PMID: 26486791 DOI: 10.1007/s11910-015-0600-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
48 Broadley I, Pera A, Morrow G, Davies KA, Kern F. Expansions of Cytotoxic CD4+CD28- T Cells Drive Excess Cardiovascular Mortality in Rheumatoid Arthritis and Other Chronic Inflammatory Conditions and Are Triggered by CMV Infection. Front Immunol 2017;8:195. [PMID: 28303136 DOI: 10.3389/fimmu.2017.00195] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 10.5] [Reference Citation Analysis]
49 Daïen CI, Fesler P. [Rheumatoid arthritis: a cardiovascular disease?]. Ann Cardiol Angeiol (Paris) 2012;61:111-7. [PMID: 21885031 DOI: 10.1016/j.ancard.2011.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
50 Wierzbicki AS, Viljoen A. Hyperlipidaemia in Paediatric Patients: The Role of Lipid-Lowering Therapy in Clinical Practice. Drug Safety 2010;33:115-25. [DOI: 10.2165/11319490-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
51 Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522-9. [PMID: 20957658 DOI: 10.1002/acr.20371] [Cited by in Crossref: 227] [Cited by in F6Publishing: 186] [Article Influence: 22.7] [Reference Citation Analysis]
52 McWilliams DF, Walsh DA. Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. BMC Musculoskelet Disord 2016;17:337. [PMID: 27515300 DOI: 10.1186/s12891-016-1192-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
53 Kawashiri S, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Nakamura H, Ida H, Origuchi T, Ueki Y, Eguchi K. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011;31:451-6. [DOI: 10.1007/s00296-009-1303-y] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
54 Giles JT. Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity? Curr Rheumatol Rep 2016;18. [DOI: 10.1007/s11926-016-0578-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M, Laghi-Pasini F. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev. 2014;13:936-944. [PMID: 24874445 DOI: 10.1016/j.autrev.2014.05.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
56 Lebwohl M. Do we need more psoriasis therapies? The Lancet 2015;386:512-4. [DOI: 10.1016/s0140-6736(15)60205-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Hartman MHT, Groot HE, Leach IM, Karper JC, van der Harst P. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc Med 2018;28:369-79. [PMID: 29519701 DOI: 10.1016/j.tcm.2018.02.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
58 Castro-sánchez P, Roda-navarro P. Physiology and Pathology of Autoimmune Diseases: Role of CD4+ T cells in Rheumatoid Arthritis. In: Rezaei N, editor. Physiology and Pathology of Immunology. InTech; 2017. [DOI: 10.5772/intechopen.70239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
59 Daudén E, Castañeda S, Suárez C, García-campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-carazo J. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermo-Sifiliográficas 2012;103:1-64. [DOI: 10.1016/s0001-7310(12)70001-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
60 Bartoloni E, Alunno A, Bistoni O, Gerli R. Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy. Clin Rev Allergy Immunol 2013;44:14-22. [PMID: 21240669 DOI: 10.1007/s12016-010-8251-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
61 González-Gay MA, González-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 2014;73:1281-3. [PMID: 24907362 DOI: 10.1136/annrheumdis-2013-204933] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
62 Tsuji S, Mukai T, Hirano H, Morita Y. In vivo analysis of thrombus formation in arthritic mice. Mod Rheumatol 2021;31:498-503. [PMID: 32149538 DOI: 10.1080/14397595.2020.1740401] [Reference Citation Analysis]
63 Sinh P, Cross R. Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1107-15. [PMID: 32978937 DOI: 10.1093/ibd/izaa258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Passacquale G, Di Giosia P, Ferro A. The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials. Cardiovasc Res 2016;109:9-23. [PMID: 26410367 DOI: 10.1093/cvr/cvv227] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
65 Hong J, Maron DJ, Shirai T, Weyand CM. Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. Int J Clin Rheumtol 2015;10:365-81. [PMID: 27042216 DOI: 10.2217/ijr.15.33] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
66 Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, Ye L, Sundy JS, Besuyen R, Meuleners L, Stanislavchuk M, Spindler AJ, Greenwald M, Alten R, Genovese MC. Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. J Rheumatol 2021;48:1230-8. [PMID: 33526618 DOI: 10.3899/jrheum.201183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
67 Karaca S, Fidan F, Erkan F, Nural S, Pinarcı T, Gunay E, Unlu M. Might psoriasis be a risk factor for obstructive sleep apnea syndrome? Sleep Breath 2013;17:275-80. [PMID: 22418840 DOI: 10.1007/s11325-012-0686-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
68 Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2009;48:1309-1313. [PMID: 19696061 DOI: 10.1093/rheumatology/kep252] [Cited by in Crossref: 261] [Cited by in F6Publishing: 212] [Article Influence: 21.8] [Reference Citation Analysis]
69 Morgan CL, Emery P, Porter D, Reynolds A, Young A, Boyd H, Poole CD, Currie CJ. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology 2013;53:186-94. [DOI: 10.1093/rheumatology/ket333] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
70 Végh E, Kerekes G, Pusztai A, Hamar A, Szamosi S, Váncsa A, Bodoki L, Pogácsás L, Balázs F, Hodosi K, Domján A, Szántó S, Nagy Z, Szekanecz Z, Szűcs G. Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. Rheumatol Int 2020;40:427-36. [DOI: 10.1007/s00296-019-04497-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
71 Paschou SA, Kothonas F, Lafkas A, Myroforidis A, Loi V, Terzi T, Karagianni O, Poulou A, Goumas K, Vryonidou A. Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease. Int J Endocrinol 2018;2018:6712901. [PMID: 29576769 DOI: 10.1155/2018/6712901] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
72 Singh S, Kullo IJ, Pardi DS, Loftus EV. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2015;12:26-35. [PMID: 25446727 DOI: 10.1038/nrgastro.2014.202] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
73 Behl T, Kaur I, Sehgal A, Zengin G, Brisc C, Brisc MC, Munteanu MA, Nistor-Cseppento DC, Bungau S. The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients. Int J Mol Sci 2020;21:E9505. [PMID: 33327502 DOI: 10.3390/ijms21249505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014;10:612-27. [DOI: 10.1038/nrrheum.2014.123] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
75 Ntusi NA, Francis JM, Sever E, Liu A, Piechnik SK, Ferreira VM, Matthews PM, Robson MD, Wordsworth PB, Neubauer S, Karamitsos TD. Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. International Journal of Cardiology 2018;270:253-9. [DOI: 10.1016/j.ijcard.2018.06.099] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
76 Lazzerini PE, Capecchi PL, Galeazzi M, Laghi-Pasini F. Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad. Immunol Res. 2016;1-14. [PMID: 27423435 DOI: 10.1007/s12026-016-8833-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
77 Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015;10:e0117952. [PMID: 25689371 DOI: 10.1371/journal.pone.0117952] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 18.3] [Reference Citation Analysis]
78 Sinagra E, Perricone G, Romano C, Cottone M. Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. Eur J Intern Med 2013;24:385-92. [PMID: 23333028 DOI: 10.1016/j.ejim.2012.12.015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
79 Vaghef-Mehrabany E, Vaghef-Mehrabany L, Asghari-Jafarabadi M, Homayouni-Rad A, Issazadeh K, Alipour B. Effects of probiotic supplementation on lipid profile of women with rheumatoid arthritis: A randomized placebo-controlled clinical trial. Health Promot Perspect 2017;7:95-101. [PMID: 28326290 DOI: 10.15171/hpp.2017.17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
80 Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Current Opinion in Rheumatology 2009;21:35-40. [DOI: 10.1097/bor.0b013e32831c5303] [Cited by in Crossref: 49] [Cited by in F6Publishing: 9] [Article Influence: 4.1] [Reference Citation Analysis]
81 Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A. Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. Autoimmunity Reviews 2011;10:631-5. [DOI: 10.1016/j.autrev.2011.04.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
82 Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, Chan C, Yusuf MA, Litwic A, Smolen S, Topliffe J, Bennett S, Humphreys J, Green M, Ledingham J. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology 2019;58:e3-e42. [DOI: 10.1093/rheumatology/key208] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
83 Atzeni F, Rodríguez-Carrio J, Popa CD, Nurmohamed MT, Szűcs G, Szekanecz Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol 2021;17:270-90. [PMID: 33833437 DOI: 10.1038/s41584-021-00593-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
84 van Vollenhoven RF. Unresolved issues in biologic therapy for rheumatoid arthritis. Nat Rev Rheumatol 2011;7:205-15. [PMID: 21386796 DOI: 10.1038/nrrheum.2011.22] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
85 Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015;67:372-380. [PMID: 25332171 DOI: 10.1002/art.38920] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 13.0] [Reference Citation Analysis]
86 Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi S, Greenberg JD. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69:1920-5. [PMID: 20444756 DOI: 10.1136/ard.2009.122226] [Cited by in Crossref: 192] [Cited by in F6Publishing: 154] [Article Influence: 17.5] [Reference Citation Analysis]
87 Curtis JR, Perez-Gutthann S, Suissa S, Napalkov P, Singh N, Thompson L, Porter-Brown B; Actemra Pharmacoepidemiology Board. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum 2015;44:381-8. [PMID: 25300699 DOI: 10.1016/j.semarthrit.2014.07.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
88 Popa CD, Arts E, Fransen J, van Riel PL. Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm 2012;2012:785946. [PMID: 22991486 DOI: 10.1155/2012/785946] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
89 Radner H. Multimorbidity in rheumatic conditions. Wien Klin Wochenschr 2016;128:786-90. [PMID: 27738754 DOI: 10.1007/s00508-016-1090-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
90 Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol 2019;15:461-74. [PMID: 31292564 DOI: 10.1038/s41584-019-0256-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 16.5] [Reference Citation Analysis]
91 Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S, Hardt K, Thaçi D, Boehncke WH. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 2011;303:381-8. [PMID: 21170539 DOI: 10.1007/s00403-010-1108-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
92 Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141. [PMID: 21884601 DOI: 10.1186/ar3455] [Cited by in Crossref: 196] [Cited by in F6Publishing: 171] [Article Influence: 19.6] [Reference Citation Analysis]
93 Hernández MV, Sanmartí R, Cañete JD. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2016;15:613-24. [PMID: 26927029 DOI: 10.1517/14740338.2016.1160054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
94 Soh MC, Nelson-Piercy C, Westgren M, McCowan L, Pasupathy D. Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus? Lupus 2017;26:1351-67. [PMID: 28728509 DOI: 10.1177/0961203317719146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
95 Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum 2014;44:345-52. [PMID: 25077842 DOI: 10.1016/j.semarthrit.2014.06.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
96 Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:362-70. [PMID: 20391482 DOI: 10.1002/acr.20105] [Cited by in Crossref: 90] [Cited by in F6Publishing: 72] [Article Influence: 8.2] [Reference Citation Analysis]
97 Al Husain A, Bruce IN. Risk factors for coronary heart disease in connective tissue diseases. Ther Adv Musculoskelet Dis 2010;2:145-53. [PMID: 22870444 DOI: 10.1177/1759720X10365301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
98 McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 2009;6:410-7. [PMID: 19421244 DOI: 10.1038/nrcardio.2009.57] [Cited by in Crossref: 169] [Cited by in F6Publishing: 149] [Article Influence: 14.1] [Reference Citation Analysis]
99 Coulson EJ, Ng W, Goff I, Foster HE. Cardiovascular risk in juvenile idiopathic arthritis. Rheumatology 2013;52:1163-71. [DOI: 10.1093/rheumatology/ket106] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
100 Corrado A, Colia R, Rotondo C, Sanpaolo E, Cantatore FP. Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-α. Curr Med Res Opin 2019;35:2197-205. [PMID: 31397188 DOI: 10.1080/03007995.2019.1654988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
101 Nurmohamed MT. Editorial: treat to target in rheumatoid arthritis: good for the joints as well as the heart? Arthritis Rheumatol 2015;67:1412-5. [PMID: 25779912 DOI: 10.1002/art.39096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
102 Brown M, Ahmed S. Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. Toxicol Appl Pharmacol 2019;370:170-7. [PMID: 30914377 DOI: 10.1016/j.taap.2019.03.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
103 Bartoloni E, Alunno A, Valentini V, Luccioli F, Valentini E, La Paglia GMC, Leone MC, Cafaro G, Marcucci E, Gerli R. Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality? Front Cardiovasc Med 2018;5:177. [PMID: 30619884 DOI: 10.3389/fcvm.2018.00177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
104 Mathieu S, Dubost JJ, Tournadre A, Malochet-Guinamand S, Ristori JM, Soubrier M. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010;77:50-2. [PMID: 20022785 DOI: 10.1016/j.jbspin.2009.05.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
105 Hyrich KL, Watson KD, Isenberg DA, Symmons DPM; on behalf of the BSR Biologics Register. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology 2008;47:1441-3. [DOI: 10.1093/rheumatology/ken242] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
106 Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, van de Kerkhof P, Ståhle M, Nestle FO, Girolomoni G, Krueger JG. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130:1785-96. [PMID: 20445552 DOI: 10.1038/jid.2010.103] [Cited by in Crossref: 396] [Cited by in F6Publishing: 332] [Article Influence: 36.0] [Reference Citation Analysis]
107 Charles-Schoeman C. Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep 2012;14:455-62. [PMID: 22791398 DOI: 10.1007/s11926-012-0271-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
108 Nguyen T, Wu JJ. Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review. Perm J 2014;18:49-54. [PMID: 24626073 DOI: 10.7812/TPP/13-092] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
109 Cacciapaglia F, Anelli MG, Rinaldi A, Fornaro M, Lopalco G, Scioscia C, Lapadula G, Iannone F. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. Mediators Inflamm 2018;2018:2453265. [PMID: 30405318 DOI: 10.1155/2018/2453265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
110 Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards CJ. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49:295-307. [PMID: 19946022 DOI: 10.1093/rheumatology/kep366] [Cited by in Crossref: 233] [Cited by in F6Publishing: 192] [Article Influence: 19.4] [Reference Citation Analysis]
111 Kisiel B, Kruszewski R, Juszkiewicz A, Raczkiewicz A, Bachta A, Tłustochowicz M, Staniszewska-Varga J, Kłos K, Duda K, Bogusławska-Walecka R, Płoski R, Tłustochowicz W. Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. J Immunol Res 2015;2015:759610. [PMID: 26090499 DOI: 10.1155/2015/759610] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
112 Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ, Tak PP. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1316-21. [PMID: 18723565 DOI: 10.1136/ard.2007.086728] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
113 Huet F, Akodad M, Fauconnier J, Lacampagne A, Roubille F. Anti-inflammatory drugs as promising cardiovascular treatments. Expert Review of Cardiovascular Therapy 2017;15:109-25. [DOI: 10.1080/14779072.2017.1273771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
114 Guenther L, Gulliver W. Psoriasis Comorbidities. J Cutan Med Surg 2009;13:S77-87. [DOI: 10.2310/7750.2009.00024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
115 Pina T, Armesto S, Lopez-mejias R, Genre F, Ubilla B, Gonzalez-lopez M, Gonzalez-vela M, Corrales A, Blanco R, Garcia-unzueta M, Hernandez J, Llorca J, Gonzalez-gay M. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol 2015;29:1325-30. [DOI: 10.1111/jdv.12814] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
116 Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS, Carroll D, Kitas GD. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2011;50:2125-39. [PMID: 21926155 DOI: 10.1093/rheumatology/ker275] [Cited by in Crossref: 91] [Cited by in F6Publishing: 75] [Article Influence: 9.1] [Reference Citation Analysis]
117 Peters MJL, Nurmohamed MT, Kitas GD, Sattar N. Statin treatment of rheumatoid arthritis: Comment on the editorial by Ridker and Solomon. Arthritis Rheum 2010;62:302-3. [DOI: 10.1002/art.25054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Churton S, Brown L, Shin TM, Korman NJ. Does Treatment of Psoriasis Reduce the Risk of Cardiovascular Disease? Drugs 2014;74:169-82. [DOI: 10.1007/s40265-013-0173-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
119 Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015;36:482-9c. [PMID: 25433021 DOI: 10.1093/eurheartj/ehu403] [Cited by in Crossref: 190] [Cited by in F6Publishing: 144] [Article Influence: 27.1] [Reference Citation Analysis]
120 Lin TT, Wu CK, Liao MT, Yang YH, Chen PC, Yeih DF, Lin LY. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study. PLoS One 2017;12:e0188720. [PMID: 29216228 DOI: 10.1371/journal.pone.0188720] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
121 Burden A. Drug survival rates for tumour necrosis factor-α antagonists in psoriasis: Commentaries. British Journal of Dermatology 2011;164:940-1. [DOI: 10.1111/j.1365-2133.2011.10355.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
122 Giles JT. Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice. Best Practice & Research Clinical Rheumatology 2015;29:597-613. [DOI: 10.1016/j.berh.2015.09.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
123 Cohen MD, Keystone E. Rituximab for Rheumatoid Arthritis. Rheumatol Ther. 2015;2:99-111. [PMID: 27747531 DOI: 10.1007/s40744-015-0016-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
124 Curtis JR, Xie F, Chen L, Saag KG, Yun H, Muntner P. Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis 2018;77:386-92. [PMID: 29269418 DOI: 10.1136/annrheumdis-2017-211727] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
125 Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmunity Reviews 2009;8:663-7. [DOI: 10.1016/j.autrev.2009.02.015] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 6.9] [Reference Citation Analysis]
126 Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:138-44. [PMID: 18349742 DOI: 10.1097/BOR.0b013e3282f4b392] [Cited by in Crossref: 84] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]
127 Amaya-Amaya J, Montoya-Sánchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. Biomed Res Int 2014;2014:367359. [PMID: 25177690 DOI: 10.1155/2014/367359] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
128 Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35:578-589. [PMID: 24026779 DOI: 10.1093/eurheartj/eht367] [Cited by in Crossref: 307] [Cited by in F6Publishing: 266] [Article Influence: 38.4] [Reference Citation Analysis]
129 Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008;159 Suppl 2:10-7. [PMID: 18700910 DOI: 10.1111/j.1365-2133.2008.08780.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 9.0] [Reference Citation Analysis]
130 Naerr GW, Rein P, Saely CH, Drexel H. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascular Pharmacology 2016;81:22-30. [DOI: 10.1016/j.vph.2016.01.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
131 Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol 2019;72:31-40. [DOI: 10.1002/art.41095] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 24.0] [Reference Citation Analysis]
132 Mahmoudi M, Aslani S, Fadaei R, Jamshidi AR. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int J Rheum Dis 2017;20:287-97. [PMID: 28205331 DOI: 10.1111/1756-185X.12999] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 7.8] [Reference Citation Analysis]
133 Girolomoni G, Griffiths CEM, Krueger J, Nestle FO, Nicolas J, Prinz JC, Puig L, Ståhle M, van de Kerkhof PCM, Allez M, Emery P, Paul C. Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. Journal of Dermatological Treatment 2014;26:103-12. [DOI: 10.3109/09546634.2014.880396] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
134 Little PJ, Chait A, Bobik A. Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacology & Therapeutics 2011;131:255-68. [DOI: 10.1016/j.pharmthera.2011.04.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
135 Radner H, Dixon W, Hyrich K, Askling J. Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers. Arthritis Care Res (Hoboken) 2015;67:1219-29. [PMID: 25892245 DOI: 10.1002/acr.22602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
136 Low AS, Symmons DP, Lunt M, Mercer LK, Gale CP, Watson KD, Dixon WG, Hyrich KL; British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:654-660. [PMID: 28073800 DOI: 10.1136/annrheumdis-2016-209784] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 18.3] [Reference Citation Analysis]
137 Gisondi P, Girolomoni G. Cardiometabolic Comorbidities and the Approach to Patients with Psoriasis. Actas Dermo-Sifiliográficas 2009;100:14-21. [DOI: 10.1016/s0001-7310(09)73373-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
138 De Mozzi P, Johnston G, Alexandroff A. Psoriasis: an evidence-based update. Report of the 9th Evidenced Based Update Meeting, 12 May 2011, Loughborough, U.K.: Report of the 9th Evidence Based Update Meeting on psoriasis. British Journal of Dermatology 2012;166:252-60. [DOI: 10.1111/j.1365-2133.2011.10767.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
139 Vena GA, Vestita M, Cassano N. Can early treatment with biologicals modify the natural history of comorbidities? Dermatologic Therapy 2010;23:181-93. [DOI: 10.1111/j.1529-8019.2010.01313.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
140 Hsu CY, Su YJ, Chen JF, Sun CC, Cheng TT, Tsai TH, Lin SH, Chang CC, Chen TH. Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome. J Am Heart Assoc 2021;10:e018290. [PMID: 33860677 DOI: 10.1161/JAHA.120.018290] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Bernardes M, Vieira TS, Martins MJ, Lucas R, Costa L, Pereira JG, Ventura F, Martins E. Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers. Biomed Res Int 2017;2017:6509754. [PMID: 28553649 DOI: 10.1155/2017/6509754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
142 Radovits BJ, Kievit W, Laan RF. Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety. Drugs Aging 2009;26:647-64. [PMID: 19685931 DOI: 10.2165/11316460-000000000-00000] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
143 Hoppe B, Dörner T. Is there a 'window of opportunity' for intervention to reduce risk of coronary artery disease in SLE? Nat Rev Rheumatol 2008;4:452-3. [DOI: 10.1038/ncprheum0879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
144 Boehncke WH, Sterry W. Psoriasis--a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives. J Dtsch Dermatol Ges 2009;7:946-52. [PMID: 19341429 DOI: 10.1111/j.1610-0387.2009.07083.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
145 Krüger K, Strangfeld A, Kneitz C. [Safety of antirheumatic drug treatment in the elderly]. Z Rheumatol 2014;73:244-50. [PMID: 24676590 DOI: 10.1007/s00393-013-1245-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
146 Hsieh MJ, Lee CH, Tsai ML, Kao CF, Lan WC, Huang YT, Tseng WY, Wen MS, Chang SH. Biologic Agents Reduce Cardiovascular Events in Rheumatoid Arthritis Not Responsive to Tumour Necrosis Factor Inhibitors: A National Cohort Study. Can J Cardiol 2020;36:1739-46. [PMID: 32603700 DOI: 10.1016/j.cjca.2020.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
147 Nakajima A, Saito K, Kojima T, Amano K, Yoshio T, Fukuda W, Inoue E, Taniguchi A, Momohara S, Minota S, Takeuchi T, Ishiguro N, Tanaka Y, Yamanaka H. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Modern Rheumatology 2014;23:945-52. [DOI: 10.3109/s10165-012-0773-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
148 Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J; Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012;64:42-52. [PMID: 21898355 DOI: 10.1002/art.30654] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
149 Kievit W, Fransen J, de Waal Malefijt MC, den Broeder AA, van Riel PL. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology (Oxford) 2013;52:1500-8. [PMID: 23657913 DOI: 10.1093/rheumatology/ket166] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
150 Kerekes G, Soltész P, Dér H, Veres K, Szabó Z, Végvári A, Shoenfeld Y, Szekanecz Z. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 2009;1173:814-21. [PMID: 19758233 DOI: 10.1111/j.1749-6632.2009.04645.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
151 Brunetti ND, De Gennaro L, Cuculo A, Gaglione A, Di Biase M. History of allergy is a predictor of adverse events in unstable angina treated with coronary angioplasty. Allergol Immunopathol (Madr) 2013;41:25-9. [PMID: 22417939 DOI: 10.1016/j.aller.2011.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
152 Pierer M, Baerwald C. Biologikatherapie bei rheumatologischen Erkrankungen. Internist 2008;49:938-46. [DOI: 10.1007/s00108-008-2059-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
153 van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R. Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. J Rheumatol 2010;37:558-67. [DOI: 10.3899/jrheum.090856] [Cited by in Crossref: 190] [Cited by in F6Publishing: 152] [Article Influence: 17.3] [Reference Citation Analysis]
154 Full LE, Monaco C. Targeting Inflammation as a Therapeutic Strategy in Accelerated Atherosclerosis in Rheumatoid Arthritis: Therapeutic Strategies for Accelerated Atherosclerosis in RA. Cardiovascular Therapeutics 2011;29:231-42. [DOI: 10.1111/j.1755-5922.2010.00159.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
155 Boehncke W, Katsambas A, Ortonne J, Puig L. EADV preceptorship: advances in dermatology: EADV preceptorship: advances in dermatology. Journal of the European Academy of Dermatology and Venereology 2010;24:2-24. [DOI: 10.1111/j.1468-3083.2010.03787.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
156 Giles JT. Extra-articular Manifestations and Comorbidity in Rheumatoid Arthritis: Potential Impact of Pre-Rheumatoid Arthritis Prevention. Clin Ther 2019;41:1246-55. [PMID: 31196641 DOI: 10.1016/j.clinthera.2019.04.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
157 Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009;4:e6242. [PMID: 19606218 DOI: 10.1371/journal.pone.0006242] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
158 Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013;9:513-23. [PMID: 23774906 DOI: 10.1038/nrrheum.2013.91] [Cited by in Crossref: 160] [Cited by in F6Publishing: 129] [Article Influence: 20.0] [Reference Citation Analysis]
159 Reimold AM. The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol 2012;4:33-47. [PMID: 27790010 DOI: 10.2147/OARRR.S14569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
160 Suarez-Gestal M, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez A. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res Ther 2010;12:R72. [PMID: 20423481 DOI: 10.1186/ar2990] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
161 Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum 2014;43:479-88. [PMID: 24080116 DOI: 10.1016/j.semarthrit.2013.08.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 8.1] [Reference Citation Analysis]
162 Bonanad C, González-parra E, Rivera R, Carrascosa J, Daudén E, Olveira A, Botella-estrada R. Implicaciones clínicas, diagnósticas y terapéuticas de la psoriasis y enfermedad cardiovascular. Actas Dermo-Sifiliográficas 2017;108:800-8. [DOI: 10.1016/j.ad.2016.12.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
163 Peluso R, Caso F, Tasso M, Sabbatino V, Lupoli R, Dario Di Minno MN, Ursini F, Costa L, Scarpa R. Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis. Open Access Rheumatol 2019;11:143-56. [PMID: 31388317 DOI: 10.2147/OARRR.S206931] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
164 Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol 2018;113:405-17. [PMID: 29336432 DOI: 10.1038/ajg.2017.479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
165 Recio-mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. European Heart Journal 2009;30:1837-43. [DOI: 10.1093/eurheartj/ehp205] [Cited by in Crossref: 135] [Cited by in F6Publishing: 90] [Article Influence: 11.3] [Reference Citation Analysis]
166 Humphreys J, Hyrich K, Symmons D. What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? Arthritis Res Ther. 2016;18:282. [PMID: 27906042 DOI: 10.1186/s13075-016-1176-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
167 Nash M, McGrath JP, Cartland SP, Patel S, Kavurma MM. Tumour necrosis factor superfamily members in ischaemic vascular diseases. Cardiovasc Res 2019;115:713-20. [PMID: 30816914 DOI: 10.1093/cvr/cvz042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
168 Van Raemdonck K, Umar S, Szekanecz Z, Zomorrodi RK, Shahrara S. Impact of obesity on autoimmune arthritis and its cardiovascular complications. Autoimmunity Reviews 2018;17:821-35. [DOI: 10.1016/j.autrev.2018.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
169 Ozen G, Pedro S, Michaud K. The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. J Rheumatol 2021;48:648-55. [PMID: 32801134 DOI: 10.3899/jrheum.200265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
170 Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Gomez-Acebo I, Testa A, Garcia-Porrua C, Sanchez-Andrade A, Llorca J, González-Gay MA. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm. 2012;2012:674265. [PMID: 22899879 DOI: 10.1155/2012/674265] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
171 Boehncke W, Gladman DD, Chandran V. Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting. J Rheumatol 2011;38:567-71. [DOI: 10.3899/jrheum.101124] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
172 Full LE, Ruisanchez C, Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2009;11:217. [PMID: 19435478 DOI: 10.1186/ar2631] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
173 Hung YM, Wang YH, Lin L, Wang PYP, Chiou JY, Wei JC. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study. Int J Clin Pract 2018;72:e13095. [PMID: 29691971 DOI: 10.1111/ijcp.13095] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
174 Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 2010;104:13-26. [DOI: 10.1093/qjmed/hcq203] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
175 Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opinion on Pharmacotherapy 2008;9:1121-8. [DOI: 10.1517/14656566.9.7.1121] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
176 Pietrzak A, Bartosińska J, Chodorowska G, Szepietowski JC, Paluszkiewicz P, Schwartz RA. Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol 2013;52:153-62. [PMID: 23347301 DOI: 10.1111/j.1365-4632.2012.05584.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
177 Moreland LW, Curtis JR. Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms. Seminars in Arthritis and Rheumatism 2009;39:132-43. [DOI: 10.1016/j.semarthrit.2008.08.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
178 Tillett W, Mchugh N. Treatment Algorithms for Early Psoriatic Arthritis: Do They Depend on Disease Phenotype? Curr Rheumatol Rep 2012;14:334-42. [DOI: 10.1007/s11926-012-0265-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
179 Teringova E, Tousek P. Apoptosis in ischemic heart disease. J Transl Med 2017;15:87. [PMID: 28460644 DOI: 10.1186/s12967-017-1191-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 19.3] [Reference Citation Analysis]
180 Atzeni F, Nucera V, Gerratana E, Cirillo M, Marino F, Miceli G, Sangari D, Boccassini L, Masala IF. Concerns about the safety of anti-TNF agents when treating rheumatic diseases. Expert Opinion on Drug Safety 2020;19:695-705. [DOI: 10.1080/14740338.2020.1763299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
181 Aukrust P, Sandberg WJ, Otterdal K, Vinge LE, Gullestad L, Yndestad A, Halvorsen B, Ueland T. Tumor necrosis factor superfamily molecules in acute coronary syndromes. Ann Med. 2011;43:90-103. [PMID: 21039303 DOI: 10.3109/07853890.2010.523711] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
182 Sugihara T, Harigai M. Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging 2016;33:97-107. [PMID: 26833350 DOI: 10.1007/s40266-015-0341-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
183 Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol 2017;69:1154-64. [PMID: 28245350 DOI: 10.1002/art.40084] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 24.3] [Reference Citation Analysis]
184 Wasko MC, Hsia EC, Kirkham B, Touboul PJ, Fleischmann R, Genovese MC, Matteson EL, Lu J, Xu W, Rahman MU. Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides. J Clin Rheumatol 2014;20:1-10. [PMID: 24356481 DOI: 10.1097/RHU.0000000000000053] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
185 Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, Hochberg MC, Tsao P, Greenberg JD. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67:1449-1455. [PMID: 25776112 DOI: 10.1002/art.39098] [Cited by in Crossref: 139] [Cited by in F6Publishing: 111] [Article Influence: 23.2] [Reference Citation Analysis]
186 Ersozlu Bozkirli ED, Bozkirli E, Yucel AE. Effects of infliximab treatment in terms of cardiovascular risk and insulin resistance in ankylosing spondylitis patients. Mod Rheumatol. 2014;24:335-339. [PMID: 24252046 DOI: 10.3109/14397595.2013.843752] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
187 Del Giudice E, Dilillo A, Tromba L, La Torre G, Blasi S, Conti F, Viola F, Cucchiara S, Duse M. Aortic, carotid intima-media thickness and flow- mediated dilation as markers of early atherosclerosis in a cohort of pediatric patients with rheumatic diseases. Clin Rheumatol 2018;37:1675-82. [PMID: 29022136 DOI: 10.1007/s10067-017-3705-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
188 Masuda H, Miyazaki T, Shimada K, Tamura N, Matsudaira R, Yoshihara T, Ohsaka H, Sai E, Matsumori R, Fukao K, Hiki M, Kume A, Kiyanagi T, Takasaki Y, Daida H. Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. J Cardiol 2014;64:366-70. [PMID: 24685688 DOI: 10.1016/j.jjcc.2014.02.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
189 Marder W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S, Brook R, Kaplan MJ. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis 2011;70:1550-5. [PMID: 21727237 DOI: 10.1136/ard.2010.148031] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
190 Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol 2020;16:361-79. [PMID: 32494054 DOI: 10.1038/s41584-020-0428-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
191 van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502. [PMID: 23136242 DOI: 10.1136/annrheumdis-2012-201956] [Cited by in Crossref: 219] [Cited by in F6Publishing: 179] [Article Influence: 24.3] [Reference Citation Analysis]
192 Masoud S, Lim PB, Kitas GD, Panoulas V. Sudden cardiac death in patients with rheumatoid arthritis. World J Cardiol 2017;9:562-73. [PMID: 28824786 DOI: 10.4330/wjc.v9.i7.562] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
193 Mócsai A, Kovács L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med 2014;12:43. [PMID: 24620738 DOI: 10.1186/1741-7015-12-43] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
194 Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013;12:1004-15. [PMID: 23541482 DOI: 10.1016/j.autrev.2013.03.013] [Cited by in Crossref: 162] [Cited by in F6Publishing: 128] [Article Influence: 20.3] [Reference Citation Analysis]
195 Alexandroff A, Graham-brown R. Report from the 67th Annual Meeting of the American Academy of Dermatology: Report of the 67th Annual Meeting of the AAD. British Journal of Dermatology 2010;162:12-21. [DOI: 10.1111/j.1365-2133.2009.09395.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
196 Bergström U, Jacobsson LT, Turesson C. Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmö, Sweden. Rheumatology (Oxford) 2009;48:1600-5. [PMID: 19858122 DOI: 10.1093/rheumatology/kep301] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
197 Abdulghani M, Al Sheik A, Alkhawajah M, Ammoury A, Behrens F, Benchikhi H, Benkaidali I, Doss N, El Gendy A, Mokhtar I, Odendaal D, Raboobee N, Thaçi D, Weiss R, Whitaker D. Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement. J Int Med Res 2011;39:1573-88. [PMID: 22117959 DOI: 10.1177/147323001103900501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
198 Haddad A, Zisman D. Comorbidities in Patients with Psoriatic Arthritis. Rambam Maimonides Med J 2017;8. [PMID: 28178440 DOI: 10.5041/RMMJ.10279] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
199 Szekanecz Z, Besenyei T, Szentpétery Á, Koch AE. Angiogenesis and vasculogenesis in rheumatoid arthritis: . Current Opinion in Rheumatology 2010;22:299-306. [DOI: 10.1097/bor.0b013e328337c95a] [Cited by in Crossref: 99] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
200 Kleinert S, Krueger K. Kardiovaskuläre Komorbidität und ihre Risikofaktoren bei rheumatoider Arthritis. Z Rheumatol 2011;70:464-72. [DOI: 10.1007/s00393-011-0755-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
201 Furer V, Fayad ZA, Mani V, Calcagno C, Farkouh ME, Greenberg JD. Noninvasive Cardiovascular Imaging in Rheumatoid Arthritis: Current Modalities and the Emerging Role of Magnetic Resonance and Positron Emission Tomography Imaging. Seminars in Arthritis and Rheumatism 2012;41:676-88. [DOI: 10.1016/j.semarthrit.2011.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
202 Drakopoulou M, Soulaidopoulos S, Oikonomou G, Tousoulis D, Toutouzas K. Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Curr Vasc Pharmacol 2020;18:488-506. [PMID: 32056527 DOI: 10.2174/1570161118666200214115532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
203 Evensen K, Aulie HA, Rønning OM, Flatø B, Russell D. Carotid Atherosclerosis in Adult Patients with Persistently Active Juvenile Idiopathic Arthritis Compared with Healthy Controls. J Rheumatol 2016;43:810-5. [DOI: 10.3899/jrheum.150499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
204 Deodhar A, Bitman B, Yang Y, Collier DH. The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis. Clin Rheumatol 2016;35:3045-52. [PMID: 27704313 DOI: 10.1007/s10067-016-3422-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
205 Xie F, Chen L, Yun H, Levitan EB, Curtis JR. Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. J Rheumatol 2021;48:804-12. [PMID: 33060309 DOI: 10.3899/jrheum.191326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
206 Pursani V, Pethe P, Bashir M, Sampath P, Tanavde V, Bhartiya D. Genetic and Epigenetic Profiling Reveals EZH2-mediated Down Regulation of OCT-4 Involves NR2F2 during Cardiac Differentiation of Human Embryonic Stem Cells. Sci Rep 2017;7:13051. [PMID: 29026152 DOI: 10.1038/s41598-017-13442-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
207 Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2012;64:1282-91. [PMID: 22504829 DOI: 10.1002/acr.21693] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
208 Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. [PMID: 18625622 DOI: 10.1136/ard.2008.092932] [Cited by in Crossref: 737] [Cited by in F6Publishing: 631] [Article Influence: 56.7] [Reference Citation Analysis]
209 Bergström U, Jovinge S, Persson J, Jacobsson LTH, Turesson C. Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. Curr Ther Res Clin Exp 2018;89:1-6. [PMID: 30128057 DOI: 10.1016/j.curtheres.2018.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
210 Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 2014;70:168-77. [PMID: 24184141 DOI: 10.1016/j.jaad.2013.09.020] [Cited by in Crossref: 88] [Cited by in F6Publishing: 67] [Article Influence: 11.0] [Reference Citation Analysis]
211 de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. Joint Bone Spine 2017;84:133-40. [PMID: 27341745 DOI: 10.1016/j.jbspin.2016.02.028] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
212 Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J Cardiol 2018;71:277-83. [PMID: 28969969 DOI: 10.1016/j.jjcc.2017.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
213 Patel KHK, Jones TN, Sattler S, Mason JC, Ng FS. Proarrhythmic electrophysiological and structural remodeling in rheumatoid arthritis. Am J Physiol Heart Circ Physiol 2020;319:H1008-20. [PMID: 32946265 DOI: 10.1152/ajpheart.00401.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
214 Solow EB, Yu F, Thiele GM, Sokolove J, Robinson WH, Pruhs ZM, Michaud KD, Erickson AR, Sayles H, Kerr GS, Gaffo AL, Caplan L, Davis LA, Cannon GW, Reimold AM, Baker J, Schwab P, Anderson DR, Mikuls TR. Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality. Rheumatology (Oxford) 2015;54:1587-95. [PMID: 25854268 DOI: 10.1093/rheumatology/kev027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
215 John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 2009;23:71-82. [DOI: 10.1016/j.berh.2008.11.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
216 van der Kooij SM, Allaart CF, Dijkmans BA, Breedveld FC. Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008;20:287-94. [PMID: 18388520 DOI: 10.1097/BOR.0b013e3282fa13db] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
217 Tocci G, Goletti D, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. Expert Opin Drug Saf 2016;15:55-61. [PMID: 27924645 DOI: 10.1080/14740338.2016.1218469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
218 Atzeni F, Gianturco L, Talotta R, Varisco V, Ditto MC, Turiel M, Sarzi-Puttini P. Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern? Immunotherapy 2015;7:353-61. [PMID: 25917627 DOI: 10.2217/imt.15.4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
219 Vizzardi E, Cavazzana I, Sciatti E, Bonadei I, D'Aloia A, Tincani A, Franceschini F, Metra M. Evaluation of ascending aorta wall in rheumatoid arthritis by tissue and strain Doppler imaging during anti-tumor necrosis factor-α therapy. Clin Cardiol 2014;37:738-43. [PMID: 25236839 DOI: 10.1002/clc.22332] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
220 Gabriel SE. Tumor necrosis factor inhibition: A part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum 2008;58:637-40. [DOI: 10.1002/art.23280] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
221 Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther 2018;20:171. [PMID: 30086795 DOI: 10.1186/s13075-018-1669-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 15.7] [Reference Citation Analysis]
222 Kitagawa T, Yamamoto H, Hattori T, Sentani K, Takahashi S, Senoo A, Kubo Y, Yasui W, Sueda T, Kihara Y. Tumor Necrosis Factor-α Gene Expression in Epicardial Adipose Tissue is Related to Coronary Atherosclerosis Assessed by Computed Tomography. J Atheroscler Thromb 2018;25:269-80. [PMID: 28931782 DOI: 10.5551/jat.41178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
223 Angel K, Provan SA, Hammer HB, Mowinckel P, Kvien TK, Atar D. Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol 2011;25:511-7. [PMID: 20825487 DOI: 10.1111/j.1472-8206.2010.00872.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
224 Coumbe AG, Pritzker MR, Duprez DA. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med 2014;127:12-8. [PMID: 24161194 DOI: 10.1016/j.amjmed.2013.08.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
225 Hassan S, Milman U, Feld J, Eder L, Lavi I, Cohen S, Zisman D. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther 2016;18:261. [PMID: 27832797 DOI: 10.1186/s13075-016-1148-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
226 Wu JJ, Joshi AA, Reddy SP, Batech M, Egeberg A, Ahlehoff O, Mehta NN. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol 2018;32:1320-6. [PMID: 29573294 DOI: 10.1111/jdv.14951] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
227 De Sanctis S, Marcovecchio ML, Gaspari S, Del Torto M, Mohn A, Chiarelli F, Breda L. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. J Rheumatol 2013;40:943-8. [PMID: 23547210 DOI: 10.3899/jrheum.121281] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
228 Benson MM, Frishman WH. The heartbreak of psoriasis: a review of cardiovascular risk in patients with psoriasis. Cardiol Rev 2015;23:312-6. [PMID: 26440534 DOI: 10.1097/CRD.0000000000000048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
229 Solomon DH, Greenberg J, Curtis JR, Liu M, Farkouh ME, Tsao P, Kremer JM, Etzel CJ. Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: A Consortium of Rheumatology Researchers of North America Registry Study: CARDIOVASCULAR RISK PREDICTION SCORE IN RHEUMATOID ARTHRITIS. Arthritis & Rheumatology 2015;67:1995-2003. [DOI: 10.1002/art.39195] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 12.8] [Reference Citation Analysis]
230 Castañeda S, Martínez Calatrava M, Herrero-beaumont G. Disyuntivas en el tratamiento de la artritis reumatoide: razones para el uso de abatacept. Revista Clínica Española 2012;212:244-54. [DOI: 10.1016/j.rce.2011.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, Shadick NS, Mehta NN. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 2015;4:e001588. [PMID: 25637346 DOI: 10.1161/JAHA.114.001588] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
232 Maruotti N, d’Onofrio F, Cantatore FP. Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy. Clin Exp Med 2015;15:433-8. [DOI: 10.1007/s10238-014-0323-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
233 van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol 2015;42:1761-6. [PMID: 26276965 DOI: 10.3899/jrheum.150051] [Cited by in Crossref: 128] [Cited by in F6Publishing: 108] [Article Influence: 21.3] [Reference Citation Analysis]
234 Ljung L, Rantapää-dahlqvist S, Jacobsson LTH, Askling J. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis 2016;75:2087-94. [DOI: 10.1136/annrheumdis-2015-208995] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
235 Grossman C, Bornstein G, Leibowitz A, Ben-zvi I, Grossman E. Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure. Blood Pressure 2017;26:24-9. [DOI: 10.1080/08037051.2016.1183460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
236 Ruiz Carrascosa JC, Arias Santiago S. Psoriasis y síndrome metabólico. Piel 2010;25:133-45. [DOI: 10.1016/j.piel.2009.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
237 Curtis JR, Chen L, Greenberg JD, Harrold L, Kilgore ML, Kremer JM, Solomon DH, Yun H. The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf 2017;26:310-9. [PMID: 28028867 DOI: 10.1002/pds.4126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
238 Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D, Boumpas DT. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol. 2009;38:6-10. [PMID: 18991190 DOI: 10.1080/03009740802363768] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 5.5] [Reference Citation Analysis]
239 Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol 2017;76:81-90. [PMID: 27894789 DOI: 10.1016/j.jaad.2016.07.042] [Cited by in Crossref: 59] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
240 Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, Bili A. Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc 2016;5:e002867. [PMID: 26727968 DOI: 10.1161/JAHA.115.002867] [Cited by in Crossref: 74] [Cited by in F6Publishing: 30] [Article Influence: 14.8] [Reference Citation Analysis]
241 Chee MM, Alcorn N, Paterson K, Madhok R. Promoting science over serendipity in prescribing anti-TNF therapy. Rheumatology 2009;48:865-6. [DOI: 10.1093/rheumatology/kep095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
242 Raychaudhuri SP. Comorbidities of psoriatic arthritis -- metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012;39:437-40. [PMID: 22298276 DOI: 10.3899/jrheum.111244] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
243 Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gómez-Reino JJ. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015;67:117-27. [PMID: 25303044 DOI: 10.1002/art.38894] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 15.2] [Reference Citation Analysis]
244 Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212. [PMID: 21321594 DOI: 10.1038/ni.2001] [Cited by in Crossref: 1286] [Cited by in F6Publishing: 1126] [Article Influence: 128.6] [Reference Citation Analysis]
245 Goodman SM. Rheumatoid Arthritis: Preoperative Evaluation for Total Hip and Total Knee Replacement Surgery. Journal of Clinical Rheumatology 2013;19:187-92. [DOI: 10.1097/rhu.0b013e318289be22] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
246 Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010;55:333-8. [PMID: 20038753 DOI: 10.1161/HYPERTENSIONAHA.109.143982] [Cited by in Crossref: 106] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
247 Rodríguez-Carrio J, Alperi-López M, López P, Ballina-García FJ, Suárez A. Good response to tumour necrosis factor alpha blockade results in an angiogenic T cell recovery in rheumatoid arthritis patients. Rheumatology (Oxford) 2015;54:1129-31. [PMID: 25832609 DOI: 10.1093/rheumatology/kev025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
248 Bartels CM, Kind AJ, Everett C, Mell M, McBride P, Smith M. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum 2011;63:1221-30. [PMID: 21305507 DOI: 10.1002/art.30239] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
249 Yoshida S, Takeuchi T, Kotani T, Yamamoto N, Hata K, Nagai K, Shoda T, Takai S, Makino S, Hanafusa T. Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens 2014;28:165-9. [DOI: 10.1038/jhh.2013.80] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
250 Strober B, Karki C, Mason M, Guo N, Holmgren SH, Greenberg JD, Lebwohl M. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. J Am Acad Dermatol 2018;78:323-32. [PMID: 29051036 DOI: 10.1016/j.jaad.2017.10.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 8.8] [Reference Citation Analysis]
251 Kang EH, Liao KP, Kim SC. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis. Curr Rheumatol Rep 2018;20. [DOI: 10.1007/s11926-018-0752-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
252 Szekanecz Z. [Personalized medicine in rheumatology]. Orv Hetil 2013;154:483-96. [PMID: 23524232 DOI: 10.1556/OH.2013.29580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
253 Daudén E, Castañeda S, Suárez C, García-campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-carazo J; on behalf of the Working Group on Comorbidity in Psoriasis. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis: Approach to comorbidity in psoriasis. Journal of the European Academy of Dermatology and Venereology 2013;27:1387-404. [DOI: 10.1111/jdv.12024] [Cited by in Crossref: 78] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
254 Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley J. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol 2014;41:2129-36. [PMID: 25086079 DOI: 10.3899/jrheum.131464] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
255 Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30. [PMID: 18325087 DOI: 10.1186/ar2383] [Cited by in Crossref: 294] [Cited by in F6Publishing: 236] [Article Influence: 22.6] [Reference Citation Analysis]
256 Tobin A, Veale DJ, Fitzgerald O, Rogers S, Collins P, O’shea D, Kirby B. Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis. J Rheumatol 2010;37:1386-94. [DOI: 10.3899/jrheum.090822] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 7.3] [Reference Citation Analysis]
257 Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol 2021;3:e58-70. [PMID: 32904897 DOI: 10.1016/S2665-9913(20)30221-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 24.0] [Reference Citation Analysis]
258 Wang H, Liu Z, Shao J, Lin L, Jiang M, Wang L, Lu X, Zhang H, Chen Y, Zhang R. Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications. J Immunol Res 2020;2020:4904217. [PMID: 32908939 DOI: 10.1155/2020/4904217] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
259 Alexandroff AB, Pauriah M, Lang CC, Struthers AD, Armstrong DJ. Atherosclerosis as a systemic feature of psoriasis: Atherosclerosis as a systemic feature of psoriasis. Clinical and Experimental Dermatology 2011;36:451-2. [DOI: 10.1111/j.1365-2230.2010.03893.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
260 Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011;165:1066-73. [PMID: 21777216 DOI: 10.1111/j.1365-2133.2011.10525.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
261 Haque S, Mirjafari H, Bruce IN. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol 2008;19:338-43. [PMID: 18607179 DOI: 10.1097/MOL.0b013e328304b65f] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
262 Plein S, Erhayiem B, Fent G, Andrews J, Greenwood J, Baxter P, Hensor EM, Pavitt S, Buch MH. Using cardiovascular magnetic resonance to define mechanisms of comorbidity and to measure the effect of biological therapy: the CADERA observational study. Efficacy Mech Eval 2021;8:1-42. [DOI: 10.3310/eme08040] [Reference Citation Analysis]
263 Atzeni F, Svenungsson E, Nurmohamed MT. Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies? Autoimmun Rev 2019;18:102401. [PMID: 31655302 DOI: 10.1016/j.autrev.2019.102401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008;159:322-30. [PMID: 18503600 DOI: 10.1111/j.1365-2133.2008.08628.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 114] [Article Influence: 10.0] [Reference Citation Analysis]
265 Damjanov N, Nurmohamed MT, Szekanecz Z. Biologics, cardiovascular effects and cancer. BMC Med 2014;12:48. [PMID: 24642038 DOI: 10.1186/1741-7015-12-48] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
266 Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60:1001-1017. [PMID: 19344980 DOI: 10.1016/j.jaad.2008.12.031] [Cited by in Crossref: 144] [Cited by in F6Publishing: 98] [Article Influence: 12.0] [Reference Citation Analysis]
267 Wang CQ, Suárez-fariñas M, Nograles KE, Mimoso CA, Shrom D, Dow ER, Heffernan MP, Hoffman RW, Krueger JG. IL-17 Induces Inflammation-Associated Gene Products in Blood Monocytes, and Treatment with Ixekizumab Reduces Their Expression in Psoriasis Patient Blood. Journal of Investigative Dermatology 2014;134:2990-3. [DOI: 10.1038/jid.2014.268] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
268 Soubrier M, Mathieu S, Bruckert E. Risque cardiovasculaire en rhumatologie : critères et scores. Revue du Rhumatisme Monographies 2010;77:176-80. [DOI: 10.1016/j.monrhu.2010.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
269 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 6] [Article Influence: 5.3] [Reference Citation Analysis]
270 Gaydukova I, Rebrov A, Nikitina N, Poddubnyy D. Decreased heart rate variability in patients with psoriatic arthritis. Clin Rheumatol 2012;31:1377-81. [PMID: 22673792 DOI: 10.1007/s10067-012-2015-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
271 Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, Gerhold K, Richter A, Listing J, Strangfeld A. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther 2016;18:183. [PMID: 27495156 DOI: 10.1186/s13075-016-1077-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
272 Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opinion on Biological Therapy 2017;17:1089-103. [DOI: 10.1080/14712598.2017.1346078] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
273 Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010;40:2-14.e1. [PMID: 20674669 DOI: 10.1016/j.semarthrit.2010.03.003] [Cited by in Crossref: 117] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
274 Herrinton LJ, Ray GT, Curtis JR, Wu JJ, Fireman B, Liu L, Goldfien R. An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches. Perm J 2018;22:17-101. [PMID: 30010538 DOI: 10.7812/TPP/17-101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
275 Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011;25:549-567. [PMID: 22137924 DOI: 10.1016/j.berh.2011.10.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 9.4] [Reference Citation Analysis]
276 Hajjaj-Hassouni N, Al-Badi M, Al-Heresh A, Al-Emadi S, El Bawendi A, El Garf A, El Hadidi K, Halabi H, Hammoudeh M, El Hassani S, Al Maaini M, Nahar I, Ladjouze Rezig A, Sellami S, Sweiri W, Alswailem R, Traub B, Uthman I, van Duuren E, Zakraoui L, El Zorkany B, Carmona L, Dougados M. The practical value of biologics registries in Africa and Middle East: challenges and opportunities. Clin Rheumatol 2012;31:407-16. [PMID: 22228237 DOI: 10.1007/s10067-011-1918-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
277 Karpouzas GA, Bui VL, Ronda N, Hollan I, Ormseth SR. Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights. Expert Rev Clin Immunol 2021;17:355-74. [PMID: 33673792 DOI: 10.1080/1744666X.2021.1899809] [Reference Citation Analysis]
278 Hollan I, Dessein PH, Ronda N, Wasko MC, Svenungsson E, Agewall S, Cohen-Tervaert JW, Maki-Petaja K, Grundtvig M, Karpouzas GA, Meroni PL. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev 2015;14:952-69. [PMID: 26117596 DOI: 10.1016/j.autrev.2015.06.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 8.5] [Reference Citation Analysis]
279 Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-489. [PMID: 25561362 DOI: 10.1136/annrheumdis-2014-206624] [Cited by in Crossref: 428] [Cited by in F6Publishing: 344] [Article Influence: 71.3] [Reference Citation Analysis]
280 Bongartz T. Tocilizumab for rheumatoid and juvenile idiopathic arthritis. The Lancet 2008;371:961-3. [DOI: 10.1016/s0140-6736(08)60428-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
281 Goodman SM, Mackenzie CR. Cardiovascular risk in the rheumatic disease patient undergoing orthopedic surgery. Curr Rheumatol Rep 2013;15:354. [PMID: 23888363 DOI: 10.1007/s11926-013-0354-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
282 Capria A, De Nardo D, Baffetti F, Barbini U, Violo A, Tondo T, Fontana L. Long-Term Anti-TNF-α Treatments Reverse the Endothelial Dysfunction in Rheumatoid Arthritis: The Biological Coherence between Synovial and Endothelial Inflammation. Int J Immunopathol Pharmacol 2010;23:255-62. [DOI: 10.1177/039463201002300123] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
283 Bäck M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 2015;12:199-211. [PMID: 25666404 DOI: 10.1038/nrcardio.2015.5] [Cited by in Crossref: 222] [Cited by in F6Publishing: 192] [Article Influence: 37.0] [Reference Citation Analysis]
284 Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G, Chowienczyk P, Kirkham B. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68:1277-1284. [PMID: 18930987 DOI: 10.1136/ard.2007.086157] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
285 Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009;161:1-7. [PMID: 19500102 DOI: 10.1111/j.1365-2133.2009.09281.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 7.9] [Reference Citation Analysis]
286 Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC. Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging. 2013;6:83-90. [PMID: 23204039 DOI: 10.1161/circimaging.112.975730] [Cited by in Crossref: 49] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
287 Di Minno MND, Iervolino S, Zincarelli C, Lupoli R, Ambrosino P, Pizzicato P, Di Minno A, Pappone N, Peluso R. Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database. Expert Opinion on Drug Safety 2015;14:1905-13. [DOI: 10.1517/14740338.2015.1111870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
288 John H, Toms TE, Kitas GD. Rheumatoid arthritis: is it a coronary heart disease equivalent? Curr Opin Cardiol 2011;26:327-33. [PMID: 21499088 DOI: 10.1097/HCO.0b013e32834703b5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
289 Nochioka K, Biering-sørensen T, Hansen KW, Sørensen R, Pedersen S, Jørgensen PG, Iversen A, Shimokawa H, Jeger R, Kaiser C, Pfisterer M, Galatius S; on behalf of the BASKET-PROVE Investigators. Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BAsel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-study. European Heart Journal: Acute Cardiovascular Care 2016;6:778-86. [DOI: 10.1177/2048872616649860] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
290 van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA, Smulders YM, Nurmohamed MT. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2011;41:393-400. [PMID: 21665247 DOI: 10.1016/j.semarthrit.2011.04.003] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
291 Kim HJ, Lebwohl MG. Biologics and Psoriasis: The Beat Goes On. Dermatol Clin 2019;37:29-36. [PMID: 30466686 DOI: 10.1016/j.det.2018.07.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
292 Boehncke W, Boehncke S, Tobin A, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity: The ‘psoriatic march’. Experimental Dermatology 2011;20:303-7. [DOI: 10.1111/j.1600-0625.2011.01261.x] [Cited by in Crossref: 266] [Cited by in F6Publishing: 225] [Article Influence: 26.6] [Reference Citation Analysis]
293 Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014;53:2143-54. [PMID: 24907149 DOI: 10.1093/rheumatology/keu224] [Cited by in Crossref: 163] [Cited by in F6Publishing: 137] [Article Influence: 23.3] [Reference Citation Analysis]
294 Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, Fichtlscherer S, Thaçi D, Boehncke WH. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25:1187-1193. [PMID: 21241371 DOI: 10.1111/j.1468-3083.2010.03947.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 7.7] [Reference Citation Analysis]
295 Bacchiega BC, Bacchiega AB, Usnayo MJ, Bedirian R, Singh G, Pinheiro GD. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Am Heart Assoc 2017;6:e005038. [PMID: 28288972 DOI: 10.1161/JAHA.116.005038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 38] [Article Influence: 16.0] [Reference Citation Analysis]
296 Monaco C, Terrando N, Midwood KS. Toll-like receptor signaling: common pathways that drive cardiovascular disease and rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:500-11. [PMID: 21452263 DOI: 10.1002/acr.20382] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
297 Pease C, Pope JE, Truong D, Bombardier C, Widdifield J, Thorne JC, Paul Haraoui B, Psaradellis E, Sampalis J, Bonner A. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum 2011;41:81-9. [PMID: 21168187 DOI: 10.1016/j.semarthrit.2010.09.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
298 Bernardi S, Marcuzzi A, Piscianz E, Tommasini A, Fabris B. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. Int J Mol Sci 2018;19:E4058. [PMID: 30558209 DOI: 10.3390/ijms19124058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
299 Hansel B, Bruckert E. Profil lipidique et risque cardiovasculaire chez les patients atteints de polyarthrite rhumatoïde : influence de la maladie et de la thérapeutique médicamenteuse. Annales d'Endocrinologie 2010;71:257-63. [DOI: 10.1016/j.ando.2010.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
300 Atzeni F, Sarzi-puttini P. Twelve years’ experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. Expert Review of Clinical Immunology 2014;8:213-22. [DOI: 10.1586/eci.12.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
301 Dhillon N, Liang K. Prevention of stroke in rheumatoid arthritis. Curr Treat Options Neurol 2015;17:356. [PMID: 25981388 DOI: 10.1007/s11940-015-0356-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
302 Chen J, Norling LV, Cooper D. Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. Cells 2021;10:881. [PMID: 33924323 DOI: 10.3390/cells10040881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
303 Welsh P, Woodward M, Rumley A, MacMahon S, Lowe GD. Does interleukin-18 or tumour necrosis factor-alpha have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand. Cytokine 2010;50:94-8. [PMID: 20096599 DOI: 10.1016/j.cyto.2009.12.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
304 Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14:R141. [PMID: 22691241 DOI: 10.1186/ar3874] [Cited by in Crossref: 98] [Cited by in F6Publishing: 82] [Article Influence: 10.9] [Reference Citation Analysis]
305 Makol A, Wright K, Matteson EL. Safe Use of Antirheumatic Agents in Patients with Comorbidities. Rheumatic Disease Clinics of North America 2012;38:771-93. [DOI: 10.1016/j.rdc.2012.08.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
306 Chih Chen Y, Rivera J, Fitzgerald M, Hausding C, Ying Y, Wang X, Todorova K, Hayrabedyan S, Barnea ER, Peter K. PreImplantation factor prevents atherosclerosis via its immunomodulatory effects without affecting serum lipids. Thromb Haemost 2017;115:1010-24. [DOI: 10.1160/th15-08-0640] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
307 Mota LMHD, Cruz BA, Brenol CV, Pollak DF, Pinheiro GDRC, Laurindo IMM, Pereira IA, Carvalho JFD, Bertolo MB, Pinheiro MDM, Freitas MVC, Silva NAD, Louzada‐júnior P, Sampaio‐barros PD, Giorgi RDN, Lima RAC, Andrade LEC. Segurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartrites. Revista Brasileira de Reumatologia 2015;55:281-309. [DOI: 10.1016/j.rbr.2014.06.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
308 Rodríguez-Rodríguez L, González-Juanatey C, Palomino-Morales R, Vázquez-Rodríguez TR, Miranda-Filloy JA, Fernández-Gutiérrez B, Llorca J, Martin J, González-Gay MA. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011;216:125-30. [PMID: 21420089 DOI: 10.1016/j.atherosclerosis.2010.10.052] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 10.1] [Reference Citation Analysis]
309 Churton SE, Doud K, Korman NJ. Comorbidities of psoriasis. Expert Review of Dermatology 2014;8:277-90. [DOI: 10.1586/edm.13.23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
310 Hung YM, Lin L, Chen CM, Chiou JY, Wang YH, Wang PY, Wei JC. The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study. PLoS One 2017;12:e0179081. [PMID: 28658301 DOI: 10.1371/journal.pone.0179081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
311 Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009;5:677-84. [DOI: 10.1038/nrrheum.2009.219] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
312 Silveira A, McLeod O, Strawbridge RJ, Gertow K, Sennblad B, Baldassarre D, Veglia F, Deleskog A, Persson J, Leander K, Gigante B, Kauhanen J, Rauramaa R, Smit AJ, Mannarino E, Giral P, Gustafsson S, Söderberg S, Öhrvik J, Humphries SE, Tremoli E, de Faire U, Hamsten A. Plasma IL-5 concentration and subclinical carotid atherosclerosis. Atherosclerosis 2015;239:125-30. [PMID: 25587992 DOI: 10.1016/j.atherosclerosis.2014.12.046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
313 Lim DT, Cannella AC, Michaud KD, Mikuls TR. Cardiovascular risk and the use of biologic agents in rheumatoid arthritis. Curr Rheumatol Rep. 2014;16:459. [PMID: 25315196 DOI: 10.1007/s11926-014-0459-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
314 Galarraga B, Khan F, Kumar P, Pullar T, Belch JJF. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology 2009;48:1418-23. [DOI: 10.1093/rheumatology/kep251] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
315 Solomon DH, Peters MJ, Nurmohamed MT, Dixon W. Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum 2013;65:1675-83. [PMID: 23606026 DOI: 10.1002/art.37975] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
316 Peters MJ, Voskuyl AE, Sattar N, Dijkmans BA, Smulders YM, Nurmohamed MT. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract 2010;64:1440-3. [PMID: 20716150 DOI: 10.1111/j.1742-1241.2009.02220.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
317 Galarraga B, Belch JJ, Pullar T, Ogston S, Khan F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J Rheumatol 2010;37:521-8. [PMID: 20080919 DOI: 10.3899/jrheum.090417] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
318 Masood F, Ehrenpreis ED, Rubin G, Russell J, Guru S, Luzzi P. State of the art review: coronary artery disease in patients with inflammatory bowel disease: mechanisms, prevalence, and outcomes. Acta Cardiol 2021;:1-11. [PMID: 34254879 DOI: 10.1080/00015385.2021.1940607] [Reference Citation Analysis]
319 Raggi P, Genest J, Giles JT, Rayner KJ, Dwivedi G, Beanlands RS, Gupta M. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis 2018;276:98-108. [DOI: 10.1016/j.atherosclerosis.2018.07.014] [Cited by in Crossref: 121] [Cited by in F6Publishing: 100] [Article Influence: 40.3] [Reference Citation Analysis]
320 Wasko MCM. Rheumatoid arthritis and cardiovascular disease. Curr Rheumatol Rep 2008;10:390-7. [DOI: 10.1007/s11926-008-0063-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
321 Christodoulidis G, Vittorio TJ, Fudim M, Lerakis S, Kosmas CE. Inflammation in coronary artery disease. Cardiol Rev 2014;22:279-88. [PMID: 24441047 DOI: 10.1097/CRD.0000000000000006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 23] [Article Influence: 8.8] [Reference Citation Analysis]
322 Pákozdi A, Besenyei T, Paragh G, Koch AE, Szekanecz Z. Endothelial progenitor cells in arthritis-associated vasculogenesis and atherosclerosis. Joint Bone Spine 2009;76:581-3. [PMID: 19945323 DOI: 10.1016/j.jbspin.2009.04.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]